Arkin Steven
Executive Director
Rare Disease and Research Unit
JDeck Inc
Belgium
Biography
Steven Arkin, MD, is Executive Director of Pfizer’s Rare Disease and Research Unit. He joined Pfizer in 2005, by way of Wyeth, and has contributed to Pfizer programs in Hemophilia and other Rare Diseases and in Oncology. For hemophilia and other rare diseases, he has led the registration program for Xyntha®, has been the research program lead for PF-05280602, variant of activated coagulation factor VII, and the clinical lead for PF-06252616, an anti-GDF8 drug targeted for Duchenne Muscular Dystrophy. In oncology he has been the clinical lead for the bosutinib programs in autosomal dominant polycystic kidney disease and in Chronic Myeloid Leukemia. Dr. Arkin is currently the research program lead for PF-05230907, a variant of activated coagulation factor X program in the clinic for treatment of intracerebral hemorrhage and the clinical lead for PF-06741086, an inhibitor of TFPI in the clinic for treatment of hemophilia. He also serves on Pfizer’s Immunogenicity Expert Working Group, is a member of the DIA Small Populations Working Group, and has served on the American Association of Pharmaceutical Scientists – Therapeutic Product Immunogenicity Committee on Harmonization of Clinical Immunogenicity.
Research Interest
Steven Arkin, MD, is Executive Director of Pfizer’s Rare Disease and Research Unit. He joined Pfizer in 2005, by way of Wyeth, and has contributed to Pfizer programs in Hemophilia and other Rare Diseases and in Oncology. For hemophilia and other rare diseases, he has led the registration program for Xyntha®, has been the research program lead for PF-05280602, variant of activated coagulation factor VII, and the clinical lead for PF-06252616, an anti-GDF8 drug targeted for Duchenne Muscular Dystrophy. In oncology he has been the clinical lead for the bosutinib programs in autosomal dominant polycystic kidney disease and in Chronic Myeloid Leukemia. Dr. Arkin is currently the research program lead for PF-05230907, a variant of activated coagulation factor X program in the clinic for treatment of intracerebral hemorrhage and the clinical lead for PF-06741086, an inhibitor of TFPI in the clinic for treatment of hemophilia. He also serves on Pfizer’s Immunogenicity Expert Working Group, is a member of the DIA Small Populations Working Group, and has served on the American Association of Pharmaceutical Scientists – Therapeutic Product Immunogenicity Committee on Harmonization of Clinical Immunogenicity.
